Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
about
Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspectiveNeoadjuvant endocrine therapy in breast cancer: current role and future perspectivesRoles for miRNAs in endocrine resistance in breast cancerThe role of androgens in experimental rodent mammary carcinogenesisHealth Services Research and Health Economy - Quality Care Training in Gynaecology, with Focus On Gynaecological OncologyMechanisms and therapeutic advances in the management of endocrine-resistant breast cancerAdjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineMain controversies in breast cancerMammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapiesSuivi après le traitement du cancer du sein: Guide pratique des soins aux survivantes à l’intention des médecins de familleFollow-up after treatment for breast cancer: Practical guide to survivorship care for family physicians[Good Prognosis! Breast Cancer Update 2016].14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.Meta-STEPP: subpopulation treatment effect pattern plot for individual patient data meta-analysis.Status of adjuvant endocrine therapy for breast cancer.Estimating efficacy in trials with selective crossover.Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.Adjuvant therapy for renal cell carcinoma: past, present, and futureUse of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancerA UK national survey of breast surgeons on primary endocrine therapy of early operable breast cancer.Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs.Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer.Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancersPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyTrefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma.The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.Clinical utility of exemestane in the treatment of breast cancerThe effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study.Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side studyComparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis.Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
P2860
Q26752834-2BE6A6A9-14BC-479D-9B3C-1B810D510DDCQ26773012-EE977D43-0ADC-433A-AAC4-98E9AA3BCD13Q26783076-BE461F85-7DE7-4BBD-8787-19D9725A46B7Q26864598-F8D259F9-0F4A-4BAB-8522-2E93F6A78229Q26996601-B4CC4F5C-E488-41A5-BC74-2E0C1BADF22FQ27001260-67DA6117-04F4-417D-951F-39649D651EBDQ27002430-53800FFB-3FAE-4D1E-90E2-67FF059068E4Q27026673-B9EB439E-FC9D-4948-8D3C-D1571F77D86AQ28074177-E39D3A71-4DEE-4F6B-AD8E-46EDCAF05C59Q28078524-96A705E3-2FAD-4E8D-A125-10FD6AC38AE2Q28080263-8F85B660-129A-4D66-8310-21A51A25AC02Q30249775-2A4C8AE8-9A3A-47DD-BE4A-7A6C17EE6A26Q30315970-42F8A0E9-F616-427F-8CA1-D6DD2FF4A46CQ30316383-E3954FC8-192B-46E4-868E-B47BFF09A334Q30860467-7F8659B6-1CEE-4C42-9394-DA0B032E8C79Q31075630-5D73A01D-0FA3-4F9A-BA2B-E67545A61863Q33739138-DD032BD4-F087-4991-9D53-862AB329FCD4Q33835695-067C289E-34DD-44D1-A145-1EE940B5F0ACQ33838622-6EABAE28-5976-4E6B-A987-816E95685859Q33921197-66075455-0398-4A6C-BBAC-32350AD39165Q34005127-74F0A86C-B71A-469D-A9F7-460C7BE2363EQ34174466-45CB8093-8157-40C2-837A-FE9E0B8A03D0Q34192638-3FEBBF81-9ECB-4FF8-B266-CEC865573EF3Q34245992-F6688B0E-E219-4314-BD8F-9DC34C408553Q34352797-1B87424E-5785-43D6-8DE4-F925C296B812Q34403564-4A6E7B61-B10D-4EB6-A839-C768C7F4DE62Q34491947-56C67F77-96CF-4F45-BC90-0733FA2B3596Q34655579-A6632F0C-9A5A-4632-90BE-E75D6B2B008EQ34764981-1B2007E4-D742-4B9F-B6C9-A221B5BC7513Q35000231-DB50C0F4-46F9-42B5-8897-E195BBF5B8A4Q35079738-FD01F01B-4C41-4829-9E20-3210D14F8D49Q35683807-AA50E38A-2233-4B6C-82E2-ADC481F9A547Q35742054-190BC097-D212-4AB6-9A9D-FF7F5E858E08Q35884159-679FFEA5-5975-41E9-8D03-252373152433Q35938880-BDE5DAA2-4283-47B6-B786-6587A9A06170Q35998828-851A680B-1B93-4C32-B21D-49CBE09B7EBBQ36095985-EE918180-F9E9-4D23-90E7-810B057258C3Q36140045-FC510268-F614-43DF-9B6C-8584F27685A3Q36316636-6B7FF0C4-2FF7-44F5-AD56-57484D4EF036Q36321147-B8EA1AF7-0D55-4200-AE5C-15EEC500CC26
P2860
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Assessment of letrozole and ta ...... at 8·1 years median follow-up.
@ast
Assessment of letrozole and ta ...... at 8·1 years median follow-up.
@en
type
label
Assessment of letrozole and ta ...... at 8·1 years median follow-up.
@ast
Assessment of letrozole and ta ...... at 8·1 years median follow-up.
@en
prefLabel
Assessment of letrozole and ta ...... at 8·1 years median follow-up.
@ast
Assessment of letrozole and ta ...... at 8·1 years median follow-up.
@en
P2093
P2860
P1433
P1476
Assessment of letrozole and ta ...... at 8·1 years median follow-up.
@en
P2093
Alan S Coates
Anita Giobbie-Hurder
Aron Goldhirsch
BIG 1-98 Collaborative Group
Beat Thürlimann
International Breast Cancer Study Group (IBCSG)
István Láng
John F Forbes
Karen N Price
P2860
P304
P356
10.1016/S1470-2045(11)70270-4
P577
2011-10-20T00:00:00Z